Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company...
PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug...
All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the Extraordinary General Meeting to be held in the coming weeks PARIS and CAMBRIDGE...
Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study in Duchenne muscular dystrophy (DMD) PARIS and CAMBRIDGE, Mass., June 13, 2019...
PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...
Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual property agreement with Stanislas Veillet PARIS and CAMBRIDGE, Mass., May 22, 2019...
PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...
Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical trial for sarcopeniaLaunch of our MYODA program for Duchenne muscular dystrophy...
PARIS, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of novel therapeutics for age-related...
(CercleFinance.com) - Biophytis annonce que la FDA (Food and Drug Administration) des Etats-Unis a accordé le statut de médicament orphelin à son candidat médicament Sarconeos dans la Dystrophie...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0021 | 0.716234652115 | 0.2932 | 0.324 | 0.293 | 26460 | 0.29495761 | DE |
| 4 | -0.0267 | -8.29192546584 | 0.322 | 0.39 | 0.28 | 60900 | 0.31230849 | DE |
| 12 | -0.1947 | -39.7346938776 | 0.49 | 0.51 | 0.28 | 42027 | 0.35159193 | DE |
| 26 | -0.4445 | -60.0838064342 | 0.7398 | 1.4 | 0.28 | 55804 | 0.53273254 | DE |
| 52 | 0.2898 | 5269.09090909 | 0.0055 | 1.4 | 0.0021 | 7597282 | 0.00598598 | DE |
| 156 | -0.2215 | -42.8599071207 | 0.5168 | 1.4 | 0.0021 | 5491182 | 0.03342074 | DE |
| 260 | 0.0663 | 28.9519650655 | 0.229 | 2.73 | 0.0021 | 4736196 | 0.27472931 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
